Omalizumab

Multi OIT to Test Immune Markers After Minimum Maintenance Dose

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

A Study to Find a Suitable Dose of Exl-111 for Further Research

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Preventing Asthma in High Risk Kids

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Omalizumab Before Onset of Exacerbations

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

Trial of JYB1904 in Patients With Allergic Asthma

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study

A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases

Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.